BLA 125409 · Genentech
Perjeta
Pertuzumab · Single-Use · HER2/neu Receptor Antagonist
NovelAccelerated approvalPriority reviewLast checked: Nov 20, 2026Latest source record: Apr 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Jun 8, 2012
Approved uses
8
Original approval plus efficacy supplements
Registered trials
381
92 Phase 3, 91 recruiting
FAERS reports
27,608
23,433 serious, 2,728 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LEFT VENTRICULAR DYSFUNCTION and EMBRYO-FETAL TOXICITY Left Ventricular Dysfunction: PERJETA can cause subclinical and clinical cardiac failure manifesting as decreased LVEF and CHF. Evaluate cardiac function prior to and during treatment. Discontinue PERJETA treatment for a confirmed clinically significant decrease in left ventricular function [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]. Embryo-fetal Toxicity: Exposure to PERJETA can cause embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception [see Warnings and Precautions (5.2) and Use in Specific Populations (8.1) (8.3) ]. WARNING: LEFT VENTRICULAR DYSFUNCTION and EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Left Ventricular Dysfunction: PERJETA can cause subclinical and...
What it is approved for
From the label in effect Apr 30, 2026.
PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.1 ) Use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.2 , 2.2 , 14.2 ) adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence ( 1.2 , 2.2 , 14.3 ) 1.1 Metastatic Breast Cancer (MBC) PERJETA is indicated for use in combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . 1.2 Early Breast Cancer (EBC) PERJETA is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.3) ] .
Mechanism: Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) and, thereby, blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4. As a result, pertuzumab inhibits ligand-initiated intracellular signaling through two major signal pathways, mitogen-activated protein (MAP) kinase, and phosphoinositide 3-kinase (PI3K). Inhibition of these signaling pathways can result in cell growth arrest and apoptosis, respectively. In addition, pertuzumab mediates...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 23, 2026 Supplement 141 · Efficacy LabelLetter
- Jan 16, 2020 Supplement 124 · Efficacy LabelLetter
- Dec 20, 2017 Supplement 113 · Efficacy LabelLetterReview
- Dec 20, 2017 Supplement 118 · Efficacy · priority review LabelLetterReview
- Mar 17, 2015 Supplement 104 · Efficacy LetterLabel
- Sep 30, 2013 Supplement 51 · Efficacy · priority review ReviewOtherSummary Review
- Apr 12, 2013 Supplement 32 · Efficacy · priority review LabelLetter
- Jun 8, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalLabelReviewLetter
1 products under this application
- PERJETA · PERTUZUMAB 420MG/14ML · VIAL, SINGLE-USE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pertuzumab" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01358877 · 4,804 participants · Start Nov 8, 2011 · Primary completion Dec 19, 2016
Drug: 5-Fluorouracil; Carboplatin and 8 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Everett, California; Greenbrae, California · 546 sites in all
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
- A Study for the Adjuvant Treatment of Breast CancerPivotal-lookingRecruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT05420467 · 2,413 participants (planned) · Start Jul 10, 2022 · Primary completion Jul 10, 2027
Drug: Docetaxel; Carboplatin and 10 more · For: Breast Cancer
Sites: Hangzhou, China
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyActive, not recruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04266249 · 2,175 participants · Start Mar 13, 2020 · Primary completion Oct 31, 2027
Drug: Docetaxel; Nab-paclitaxel and 4 more · For: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8 and 6 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,008 sites in all
- A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation ModelPivotal-lookingNot yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07239271 · 2,000 participants (planned) · Start Nov 16, 2025 · Primary completion Dec 2027
Drug: The control group; Adaptive therapy of de-escalation and escalation based on imaging and molecular analysis for predicting response · For: Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea3,873
- off label use2,424
- nausea1,996
- fatigue1,951
- myelosuppression1,628
- alopecia1,587
- disease progression1,380
- vomiting1,323
- dyspnoea1,213
- neuropathy peripheral1,146
- death1,119
- pyrexia1,078
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2009 | 6 |
| 2010 | 19 |
| 2011 | 22 |
| 2012 | 128 |
| 2013 | 679 |
| 2014 | 734 |
| 2015 | 922 |
| 2016 | 1,184 |
| 2017 | 1,909 |
| 2018 | 2,175 |
| 2019 | 2,290 |
| 2020 | 2,531 |
| 2021 | 2,951 |
| 2022 | 2,699 |
| 2023 | 2,753 |
| 2024 | 3,065 |
| 2025 | 2,025 |
| 2026 | 1,515 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Perjeta (Pertuzumab)
2024 spending
$10.4M
Beneficiaries
236
1,480 claims
Per beneficiary
$44,098
$458.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,134,840 |
| 2021 | $6,485,758 |
| 2022 | $9,467,576 |
| 2023 | $10,637,425 |
| 2024 | $10,407,108 |
Part B: Perjeta (Pertuzumab) · HCPCS J9306
2024 spending
$297M
Beneficiaries
5,766
41,163 claims
Per beneficiary
$51,528
2024 ASP limit $15.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $303,275,858 |
| 2021 | $299,033,794 |
| 2022 | $317,335,124 |
| 2023 | $308,718,219 |
| 2024 | $297,110,320 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Tolaney SM, Jiang Z, Zhang Q, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Equivalence Trial
- Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
Harbeck N, Modi S, Pusztai L, et al. · Ann Oncol 2026 · Clinical Trial, Phase III, Multicenter Study
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, et al. · Lancet Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
- HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.
Dieras V, Curigliano G, Martin M, et al. · J Clin Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Hurvitz SA, Hegg R, Chung WP, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.